Human Genome Sciences (HGSI)
- Nasdaq: HGSI
- Mkt.Cap.:5.64B
Sector Pure-Play:
Healthcare > Biopharmaceuticals (^BPHRM)
Healthcare > Biopharmaceuticals (^BPHRM) Classification
| Sector | |
|---|---|
Healthcare |
|
Biopharmaceuticals |
|

- - Focused

- - Sector Pure-Play
Sector companies
Top 5 competitive companies in Biopharmaceuticals (^BPHRM) :
| Ticker | Name | Mkt.Cap. |
|---|---|---|
| PFE | Pfizer Inc. | 133.11B |
| NVS | Novartis AG (ADR) | 122.38B |
| RHHBY | Roche Holding Ltd. (ADR) | 121.62B |
| MRK | Merck & Co., Inc. | 110.07B |
| GSK | GlaxoSmithKline plc (ADR) | 101.52B |
Relationships
Sample 8 relationships grouped by relationhip type.
| Ticker | Name | |
|---|---|---|
| Competitors | ||
![]() | SNGX | Soligenix, Inc. |
![]() | FLML | Flamel Technologies S.A. (ADR) |
| Customers | ||
![]() | GSK | GlaxoSmithKline plc (ADR) |
![]() | NVS | Novartis AG (ADR) |
| Suppliers | ||
![]() | Aegera Therapeutics, Inc. | |
![]() | DYAX | Dyax Corp. |
| Partners | ||
![]() | GSK | GlaxoSmithKline plc (ADR) |
![]() | NVS | Novartis AG (ADR) |

- - Defined by the Company

- - Defined by Others
Products & Services
Sample products & services from Biopharmaceuticals (^BPHRM) :
- ABthrax (Raxibacumab)
- Benlysta (Belimumab)/Formerly LymphoStat-B
- Darapladib (Lp-PLA2 Inhibitor)
Relative Performance (1Y)
- Human Genome Sciences (HGSI)
- S&P 500 INDEX (SPX)
- Healthcare > Biopharmaceuticals (^BPHRM)
Subscribe to an RSS Feed Research Reports
- Competitors by Product for Human Genome Sciences (HGSI) Revere - Sep 04, 2010 - HTML - $75.00 - Add to Cart »
- Drug/Medical Device for Human Genome Sciences (HGSI) Revere - Sep 04, 2010 - PDF - $70.00 - Add to Cart »
- FDA Approval Decisions Report for August, 2010 Revere - Aug 01, 2010 - ZIP - $125.00 - Add to Cart »
- FDA Approval Decisions Report for December, 2009 Revere - Dec 01, 2009 - ZIP - $125.00 - Add to Cart »
- FDA Approval Decisions Report for July, 2010 Revere - Jul 01, 2010 - ZIP - $125.00 - Add to Cart »
Healthcare
Biopharmaceuticals